Table 1 Baseline characteristics of each study compared to the validation study
Study | Number of patients | Mean age | % Male | Stage of disease | Utility - Mean (SD) [range] |
|---|---|---|---|---|---|
AURA 2 | 203 | 63.0 | 31.0 | I/II 10% III 14% IV 75% | 0.789 (0.219) [− 0.594 to 1] |
AURA 3 | 391 | 61.4 | 36.3 | I/II 10% III 10% IV 80% | 0.808 (0.209) [−0.594 to 1] |
AURA2/AURA3 combined | 594 | 61.9 | 34.5 | I/II 10% III 11% IV 78% | 0.799 (0.214 [−0.594 to 1] |
Young et al. (2015) | 771 | 68.3 | 44.1 | NR | 0.58 (0.342) [− 0.594 to 1] |
Khan and Morris (2014) | 670 | 77 | NR | I/II 0% III/IV 100% | 0.61 (0.29) [−0.043 to 1] |
Khan et al. (2016) | 98 | 69 | 44 | I/II 27% III 32% IV 38% | 0.515 (0.308) [−0.594 to 1] |